GeoVax Labs (NASDAQ:GOVX) Given Buy Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a research report released on Friday,Benzinga reports. They currently have a $18.00 target price on the stock.

GeoVax Labs Stock Down 12.6 %

Shares of NASDAQ GOVX opened at $1.11 on Friday. GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18. The stock’s 50-day simple moving average is $1.67 and its 200-day simple moving average is $2.14.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.49. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $2.38 million. Research analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in shares of GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after purchasing an additional 33,440 shares in the last quarter. Citadel Advisors LLC acquired a new stake in GeoVax Labs during the fourth quarter valued at approximately $104,000. Virtu Financial LLC acquired a new stake in GeoVax Labs during the third quarter valued at approximately $97,000. Finally, Northern Trust Corp acquired a new position in shares of GeoVax Labs in the 4th quarter worth approximately $29,000. 6.09% of the stock is owned by institutional investors and hedge funds.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.